Yi Zhang

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 19

Top Topics

Systematic Review

Top Venues

Hepatology (Baltimore, Md.)

Expert review of clinical immunology

Nanomedicine (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Zheng Li, Yi Zhang, Ying Li, Jie Lan, Yuzhu Hu, Qianqian Meng, Laraib Nadeem, Bingwen Zou
Letter to the Editor: The causal analysis of missing confounding factors for the association between HDV and specific liver events. Hepatology (Baltimore, Md.) (2024)
Yi Zhang, Zheng Li, Xi Chen, Ying Huang, Bingwen Zou, Yong Xu
Prognostic significance of FAT10 expression in malignant tumors: a systematic review and meta-analysis. Future oncology (London, England) (2024)
Zheng Li, Yi Zhang, Ying Li, Jie Lan, Yuzhu Hu, Jiayun Yu, Qianqian Meng, Bingwen Zou
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC. Hepatology (Baltimore, Md.) 79 (6) (2024)
Yi Zhang, Zheng Li, Ying Huang, Bingwen Zou, Yong Xu
Prognostic significance of cyclin-dependent kinase subunit 2 (CKS2) in malignant tumours: a meta-analysis and bioinformatic analysis. BMJ open 14 (1) (2024)
Zheng Li, Yi Zhang, Ying Li, Xi Chen, Jie Hu, Jiayun Yu, Yuzhu Hu, Shihong Nie, Nanjing Li, Qinglian Wen, Bingwen Zou
Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC? Hepatology (Baltimore, Md.) 80 (3) (2024)
Yi Zhang, Zheng Li, Ying Huang, Bingwen Zou, Yong Xu
Prognostic significance of cyclin-dependent kinase subunit 2 (CKS2) in malignant tumours: a meta-analysis and bioinformatic analysis. BMJ open 14 (1) (2024)
Zheng Li, Yi Zhang, Ying Li, Xi Chen, Jie Hu, Jiayun Yu, Yuzhu Hu, Shihong Nie, Nanjing Li, Qinglian Wen, Bingwen Zou
Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC? Hepatology (Baltimore, Md.) (2024)
Yi Zhang, Zheng Li, Xi Chen, Ying Huang, Bingwen Zou, Yong Xu
Prognostic value of NOB1 expression levels in various cancers: a systematic review and meta-analysis. Biomarkers in medicine (2024)
Yi Zhang, Zheng Li, Ying Huang, Yong Xu, Bingwen Zou
Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions. Expert review of clinical immunology 20 (8) (2024)
Yi Zhang, Zheng Li, Ying Huang, Yong Xu, Bingwen Zou
Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions. Expert review of clinical immunology 20 (8) (2024)
Yi Zhang, Zheng Li, Ying Huang, Bingwen Zou, Yong Xu
Prognostic significance of cyclin-dependent kinase subunit 2 (CKS2) in malignant tumours: a meta-analysis and bioinformatic analysis. BMJ open 14 (1) (2024)
Zheng Li, Yi Zhang, Ying Li, Xi Chen, Jie Hu, Jiayun Yu, Yuzhu Hu, Shihong Nie, Nanjing Li, Qinglian Wen, Bingwen Zou
Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC? Hepatology (Baltimore, Md.) 80 (3) (2024)
Yi Zhang, Zheng Li, Ying Huang, Bingwen Zou, Yong Xu
Prognostic significance of cyclin-dependent kinase subunit 2 (CKS2) in malignant tumours: a meta-analysis and bioinformatic analysis. BMJ open 14 (1) (2024)
Yi Zhang, Zheng Li, Ying Huang, Yong Xu, Bingwen Zou
Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions. Expert review of clinical immunology (2024)
Zheng Li, Yi Zhang, Ying Li, Jie Lan, Yuzhu Hu, Jiayun Yu, Qianqian Meng, Bingwen Zou
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC. Hepatology (Baltimore, Md.) (2024)
Yi Zhang, Xi Chen, Binbin Hu, Bingwen Zou, Yong Xu
Advancements in nanomedicine delivery systems: unraveling immune regulation strategies for tumor immunotherapy. Nanomedicine (London, England) (2024)
Yi Zhang, Zheng Li, Xi Chen, Ying Huang, Bingwen Zou, Yong Xu
Prognostic value of NOB1 expression levels in various cancers: a systematic review and meta-analysis. Biomarkers in medicine 18 (13-14) (2024)
Yi Zhang, Zheng Li, Bingwen Zou
Radiation and resolve: unlocking the synergistic potential of radioimmunotherapy in advanced lung cancer management. Immunotherapy (2023)
Yi Zhang, Zheng Li, Ying Huang, Yong Xu, Bingwen Zou
Nanotechnology and curcumin: a novel and promising approach in digestive cancer therapy. Nanomedicine (London, England) (2023)